Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-LTE: Long-Term Extension Study of ENTR-601-44 and ENTR-601-45 in Duchenne Muscular Dystrophy
NCT07682129Phase 2Not yet recruiting
- Sponsor
- Entrada Therapeutics
- Start
- Aug 2026
- Primary completion
- Mar 2032
- Countries
- 5
01
Overview
A Phase 2 trial of ENTR-601-44, ENTR-601-45 in Duchenne muscular dystrophy (DMD), sponsored by Entrada Therapeutics. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ENTR-601-44ENTR-601-45
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07682129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682129.